Palvella Therapeutics (PVLA) EBT Margin (2016 - 2024)
Historic EBT Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 2182.87%.
- Palvella Therapeutics' EBT Margin rose 11173600.0% to 2182.87% in Q4 2024 from the same period last year, while for Dec 2024 it was 13620.31%, marking a year-over-year increase of 136436600.0%. This contributed to the annual value of 4054.42% for FY2024, which is 40107600.0% up from last year.
- Palvella Therapeutics' EBT Margin amounted to 2182.87% in Q4 2024, which was up 11173600.0% from 4784.91% recorded in Q1 2024.
- Palvella Therapeutics' 5-year EBT Margin high stood at 2182.87% for Q4 2024, and its period low was 4784.91% during Q1 2024.
- In the last 5 years, Palvella Therapeutics' EBT Margin had a median value of 160.69% in 2021 and averaged 303.4%.
- Its EBT Margin has fluctuated over the past 5 years, first surged by 12565500bps in 2023, then tumbled by -40309800bps in 2024.
- Quarter analysis of 5 years shows Palvella Therapeutics' EBT Margin stood at 660.79% in 2020, then soared by 80bps to 130.34% in 2021, then plummeted by -47bps to 191.04% in 2022, then skyrocketed by 658bps to 1065.51% in 2023, then skyrocketed by 105bps to 2182.87% in 2024.
- Its EBT Margin was 2182.87% in Q4 2024, compared to 4784.91% in Q1 2024 and 1065.51% in Q4 2023.